Evidence map›Paper›PMID 36341354›Full record

ArticleFrontiers in immunology2022

Effects of hypoxia on antigen presentation and T cell-based immune recognition of HPV16-transformed cells.

Nitya Mohan, Kathrin Wellach, Ceren Özerdem, Nisha Veits, Jonas D Förster, Sophia Foehr, Maria Bonsack, Angelika B Riemer

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nitya MohanImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Kathrin WellachImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ceren ÖzerdemImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nisha VeitsImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jonas D FörsterImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sophia FoehrImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maria BonsackImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Angelika B RiemerImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEGerman Center for Infection Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Attempts to develop a therapeutic vaccine against human papillomavirus (HPV)-induced malignancies have mostly not been clinically successful to date. One reason may be the hypoxic microenvironment present in most tumors, including cervical cancer. Hypoxia dysregulates the levels of human leukocyte antigen (HLA) class I molecules in different tumor entities, impacts the function of cytotoxic T cells, and leads to decreased protein levels of the oncoproteins E6 and E7 in HPV-transformed cells. Therefore, we investigated the effect of hypoxia on the presentation of HPV16 E6- and E7-derived epitopes in cervical cancer cells and its effect on epitope-specific T cell cytotoxicity. Hypoxia induced downregulation of E7 protein levels in all analyzed cell lines, as assessed by Western blotting. However, contrary to previous reports, no perturbation of antigen processing and presentation machinery (APM) components and HLA-A2 surface expression upon hypoxia treatment was detected by mass spectrometry and flow cytometry, respectively. Cytotoxicity assays performed in hypoxic conditions showed differential effects on the specific killing of HPV16-positive cervical cancer cells by epitope-specific CD8

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsAntigen PresentationEpitopes, T-LymphocyteFemaleHistocompatibility Antigens Class IHuman papillomavirus 16HumansHypoxiaPapillomaviridaeTumor MicroenvironmentEpitopes, T-LymphocyteHistocompatibility Antigens Class Iantigen processing and presentation machinery (APM)cytotoxic T cellshuman papillomavirus (HPV)Hypoxiatumor microenvironment (TME)

Identifiers

PMID36341354
PMCPMC9634485
OpenAlexW4306973582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.